Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00829413
Other study ID # BR1-130
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 2010
Est. completion date July 2013

Study information

Verified date November 2017
Source Bracco Diagnostics, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate the Sensitivity and Specificity of SonoVue®-enhanced ultrasound is superior to that of unenhanced ultrasound for the characterization of benign versus malignant FLLs using final diagnosis based on histology or combined imaging (CE-CT and/or CE MRI)/clinical data as truth standard.


Description:

Unit of analysis for the outcome measures was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.


Recruitment information / eligibility

Status Completed
Enrollment 353
Est. completion date July 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male/female.

- Provides written Informed Consent and is willing to comply with protocol requirements.

- Is at least 18 years of age.

- Has at least 1 FLL (target lesion) requiring work-up for characterization. Target lesions may include those:

Incidentally detected, In subjects with chronic hepatitis or liver cirrhosis, In subjects with known history of malignancy.

- Is scheduled for surgical removal or biopsy of the target lesion from 24 hours to 30 days after the SonoVue® administration OR

- In case tissue biopsy is not indicated nor surgery planned, is scheduled for or has performed a CE-CT and/or CE-MRI of the target lesion from 30 days to 48 hours prior to or from 24 hours to 30 days after the administration of SonoVue®.

Exclusion Criteria:

- Has an acoustic window insufficient for adequate ultrasound examination of the liver.

- Has a FLL that cannot be identified with unenhanced ultrasound.

- Has received or is scheduled for antineoplastic chemotherapy or an invasive procedure in the time period between test procedures and truth standard assessments which may have modified the target lesion.

- Is receiving any other contrast medium, within the 48 hours before and up to 24 hours following the administration of SonoVue®.

- Has previously been enrolled in and completed this study.

- Known right to left cardiac shunt, bidirectional or transient.

- Has any known allergy to 1 or more of the ingredients of the investigational product (sulfur hexafluoride or to any components of SonoVue®).

- Has any contraindication to 1 of the planned imaging procedures (ultrasound, CT or MRI), e.g., implants, claustrophobia, inadequate medical conditions etc.

- Has received an investigational compound within 30 days before admission into this study.

- Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.

- Is determined by the Investigator that the subject is clinically unsuitable for the study.

- Is a pregnant or lactating female. Exclude the possibility of pregnancy by:

testing on site at the institution serum ßHCG within 24 hours prior to the start of SonoVue® administration, surgical history (e.g., tubal ligation or hysterectomy), post menopausal with a minimum 1 year without menses.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SonoVue®
SonoVue (2.4 mL)

Locations

Country Name City State
United States Bracco Diagnostics Inc. Princeton New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Bracco Diagnostics, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs) using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-diagnose (ITD) population. Unit of analysis was the lesion, equivalent to subject, since each subject had a single lesion to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: CE-CT and/or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100
24 hours to 6 months
Primary Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard' Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.
Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Among the 259 ITD participants, only 140 participants (lesions) were benign based on the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100.
24 hours to 6 months
Secondary Accuracy: Percentage of True Positive and True Negative Among All Lesions Accuracy of SonoVue-enhanced versus unenhanced ultrasound for characterization of malignant and benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.
Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive and true negative lesions/number of total lesions per truth standard) x 100.
24 hours to 6 months
Secondary Positive Predictive Value [PPV]: Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound Positive Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up.
Calculated as (number of true positive lesions/number of malignant lesions per ultrasound) x 100.
24 hours to 6 months
Secondary Negative Predictive Value [NPV]: Percentage of True Negative Lesions Among All Benign Lesions Per Ultrasound Negative Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per ultrasound) x 100.
24 hours to 6 months
Secondary Specific Diagnosis of Malignant FLLs SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of malignant FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.
24 hours to 6 months
Secondary Specific Diagnosis of Benign FLLs SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Among the 140 ITD participants with benign lesions based on the truth standard, only 91 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.
24 hours to 6 months
Secondary Inter-reader Agreement Kappa statistic based on assessment of malignant or benign by unenhanced and SonoVue-enhanced ultrasonography separately and computation for the percentage agreement within two categories: "3 out of 3 readers agree" and "2 out of 3 readers agree". 24 hours to 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Not yet recruiting NCT03592550 - The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
Not yet recruiting NCT02521129 - A New Track Ablation Device for Liver Biopsy: A Feasibility Study Phase 1/Phase 2
Not yet recruiting NCT02168608 - Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy N/A
Enrolling by invitation NCT01465425 - Extracolonic Findings on Computed Tomography (CT) Colonography
Active, not recruiting NCT01177007 - Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors Phase 2
Completed NCT00788697 - SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization Phase 3
Recruiting NCT01564810 - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase 4
Completed NCT00094003 - Study of NS-9 in Patients With Liver Metastases Phase 1
Terminated NCT00051532 - Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma N/A
Completed NCT00001587 - A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver Phase 1
Completed NCT00222664 - Qidong Hepatitis B Intervention Study Phase 4
Recruiting NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC Phase 2
Completed NCT03289273 - Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Terminated NCT03349255 - Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma Phase 1
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Recruiting NCT03715517 - Spinal Anesthesia For Enhanced Recovery After Liver Surgery N/A
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Terminated NCT01744054 - Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization Phase 1
Active, not recruiting NCT02969096 - Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma Phase 2